AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy
Tumor-cell AXL-upregulation correlated with distinct oncotypes and microenvironmental immune-profiles that define chemotherapy-induced mechanisms of ICI-resistance, which suggests the combination of AXL inhibitors with current chemoimmunotherapy regimens can benefit NSCLC patients.
Authors
- James B. Lorens (ORCID: https://orcid.org/0000-0002-6782-3349)
- David Micklem (ORCID: https://orcid.org/0000-0003-2756-2591)
- Maria Ramnefjell (ORCID: https://orcid.org/0009-0000-6142-6353)
- Agnete S. T. Engelsen (ORCID: https://orcid.org/0000-0003-0375-3406)
- Marianne Aanerud (ORCID: https://orcid.org/0000-0003-1337-7440)
- Austin Rayford
- Fabian Gärtner
Institutions
- Haukeland University Hospital (NO)
- BerGenBio (Norway) (NO)
- University of Bergen (NO)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-08-21
- DOI
- https://doi.org/10.3389/fimmu.2024.1444007
- Citations
- 14
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 3.37
Funders
- Universitetet i Bergen
- Norges Forskningsråd
- Haukeland Universitetssjukehus